Antidepressant-like potential of silymarin and silymarin-sertraline combination in mice: Highlighting effects on behaviour, oxidative stress, and neuroinflammation

doi:10.5497/wjp.v11.i3.27

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5423)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-9) series, Tables (1-2) series.

Item

Count

PDF

144

WORD

108

HTML

2494

Figures (1-9)

163

Tables (1-2)

191

Sum=3100

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

281

Download

983

Sum=1264

Publishing Process of This Article

Item

Count

Browse

357

Download

702

Sum=1059

Nov 28, 2022 (publication date) through Dec 4, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Pharmacol. Nov 28, 2022; 11(3): 27-47
Published online Nov 28, 2022. doi: 10.5497/wjp.v11.i3.27

Table 2 Brain levels of inflammatory markers, acetylcholinesterase activity, lipid peroxidation, and antioxidant status

Group	TNF-α ng/g/protein	IL-10 pg/mg/protein	ACHe nmol/mg	MDA nmol/g/protein	GSH nmol/mg/protein	GPx mU/mg/protein
Control	38.78 ± 0.20	23.89 ± 0.20	32.10 ± 1.30	7.95 ± 0.50	0.75 ± 0.10	18.68 ± 1.10
SERT	24.12 ± 0.10^a	19.20 ± 0.16^a	28.19 ± 1.03^a	8.01 ± 0.51	0.73 ± 0.11	17.60 ± 1.01
SILY 140	34.18 ± 0.10^a	23.65 ± 0.20	24.22 ± 1.15^a^,^b	6.91 ± 0.70^a	0.92 ± 0.05^a^,^b	34.54 ± 0.44^a^,^b
SILY 280	33.11 ± 0.20^a	23.80 ± 0.30	20.18 ± 1.15^a^,^b	5.83 ± 0.63^a^,^b	1.23 ± 0.05^a^,^b	46.20 ± 0.54^a^,^b
DEX	18.78 ± 0.13^a	9.07 ± 0.10^a	52.10 ± 1.25^a	18.20 ± 0.56^a	0.30 ± 0.05^a	10.15 ± 0.80^a
DEX/SERT	19.40 ± 0.10^a^,^c	8.21 ± 0.19^a	42.30 ± 1.11^a^,^c	18.25 ± 0.76^a^,^c	0.32 ± 0.02^a	9.89 ± 0.80^c
DEX/SILY 140	25.22 ± 0.11^c^,^d	15.22 ± 0.20^c^,^d	33.22 ± 1.24^c^,^d	7.60 ± 0.80^c^,^d	0.64 ± 0.03^a^,^c	12.40 ± 0.83^a^,^c^,^d
DEX/SILY 280	29.00 ± 0.12^a^,^c^,^d	19.21 ± 0.23^c^,^d	30.17 ± 1.13^a^,^c^,^d	6.57 ± 0.63^a^,^c^,^d	0.88 ± 0.03^c^,^d	14.35 ± 0.07^a^,^c^,^d
DEX/SERT/SILY 140	23.23 ± 0.10^a^,^c^,^d	14.10 ± 0.12^a^,^c^,^d	28.12 ± 1.21^c^,^d	6.38 ± 0.61^a^,^c^,^d	0.78 ± 0.01^a^,^c^,^d	13.42 ± 0.71^a^,^c^,^d
DEX/SERT/SILY 280	25.12 ± 0.10^a^,^c^,^d	16.19 ± 0.15^a^,^c^,^d	24.20 ± 1.10^a^,^c^,^d	6.32 ± 0.50^a^,^c^,^d	0.88 ± 0.03^a^,^c^,^d	15.42 ± 0.89^a^,^c^,^d

Values are expressed as the mean ± SEM.

^aP < 0.05 vs control.

^bP < 0.05 vs SERT.

^cP < 0.05 vs DEX.

^dP < 0.05 vs DEX/SERT. GPx: Glutathione peroxidase; MDA: Malondialdehyde; SERT: Sertraline; DEX: Dexamethasone; SILY: Silymarin. Number of mice per treatment.

Citation: Onaolapo AY, Sulaiman H, Olofinnade AT, Onaolapo OJ. Antidepressant-like potential of silymarin and silymarin-sertraline combination in mice: Highlighting effects on behaviour, oxidative stress, and neuroinflammation. World J Pharmacol 2022; 11(3): 27-47
URL: https://www.wjgnet.com/2220-3192/full/v11/i3/27.htm
DOI: https://dx.doi.org/10.5497/wjp.v11.i3.27